Journal article

Selection of chronic hepatitis B therapy with high barrier to resistance

Robert Gish, Ji-Dong Jia, Stephen Locarnini, Fabien Zoulim

The Lancet Infectious Diseases | ELSEVIER SCI LTD | Published : 2012

Grants

Funding Acknowledgements

RG has received consulting fees from Bristol-Myers Squibb, Gilead, and Roche, and lecture fees from Genentech, Roche, Gilead, Bristol-Myers Squibb, and GlaxoSmithKline. J-DJ has participated in consulting activities organised by Bristol-Myers Squibb, GlaxoSmithlaine, MSD, Novartis, and Roche. SL has participated in consulting activities organised by Evivar, Gilead, Bristol-Myers Squibb, and MSD, and has received royalties from and holds patents with Melbourne Health. FZ has received consulting fees from Gilead, Bristol-Myers Squibb, Novartis, and Roche, and lecture fees from Roche, Gildea, and Bristol-Myers Squibb.